https://mepa8.com/ Approvals, trials, guidelines and hospital news, written from primary sources and linked to them.en-us Thu, 22 Oct 2026 00:29:02 GMT https://mepa8.com/medicine/2026/10/21/hibsago-bepirovirsen-fda-approval-for-chronic-hepatitis-b/ https://mepa8.com/medicine/2026/10/21/hibsago-bepirovirsen-fda-approval-for-chronic-hepatitis-b/ Wed, 21 Oct 2026 20:27:14 GMTMedicine Mepa8 Newsroom In two placebo-controlled trials, 24% of patients on the drug met criteria to stop all hepatitis B therapy, and 19% still had the virus under control 24 weeks later, the FDA said.